77455-30-2

Upstream product

• 15548-45-5 (2S,3S,4S,5S,6R)-2-benzyloxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol 
• 76-83-5 trityl chloride 
• 50-99-7 D-mannitol 
• 86196-36-3 benzyl α-D-galactopyranoside 
• 100-51-6 benzyl alcohol 
• 3458-28-4 D-Mannose 
• 530-26-7 D-Mannose 

Downstream Products

• 78561-22-5 benzyl 2,3,4-tri-O-benzyl-6-O-triphenylmethyl-α-D-mannopyranoside 
• 77455-31-3 benzyl 3-O-allyl-6-O-trityl-α-D-mannopyranoside 
• 77469-41-1 benzyl 2-O-allyl-6-O-trityl-α-D-mannopyranoside 
• 96733-85-6 benzyl 2,3-di-O-allyl-6-O-trityl-α-D-mannopyranoside 
• 79999-52-3 benzyl O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1<*>4)-O-(3,6-di-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1<*>6)-2,3,4-tri-O-benzyl-α-D-mannopyranoside 
• 78561-24-7 benzyl O-β-D-galactopyranosyl-(1<*>4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1<*>6)-2,3,4-tri-O-benzyl-α-D-mannopyranoside 
• 78561-23-6 benzyl O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1<*>4)-O-(2-acetamido-3,6-di-O-acetyl-2-deoxy-β-D-glucopyranosyl)-(1<*>6)-2,3,4-tri-O-benzyl-α-D-mannopyranoside 
• 84073-63-2 Benzyl 3-O-phenyl-6-O-trityl-α-D-mannopyranoside-2,4-diacetate 
• 111549-76-9 (2S,3S,4S,5S,6S)-4-Allyloxy-3,5,6-tris-benzyloxy-tetrahydro-pyran-2-carbaldehyde 
• 77455-33-5 benzyl 3-O-allyl-2,4-di-O-benzyl-α-D-mannopyranoside 
• 111549-79-2 benzyl 2,4,6,7-tetra-O-benzyl-L-glycero-α-D-mannoheptopyranoside 
• 111549-78-1 (2S,3S,4S,5S,6R)-4-Allyloxy-2,3,5-tris-benzyloxy-6-((S)-1,2-bis-benzyloxy-ethyl)-tetrahydro-pyran 
• 111549-75-8 benzyl 3-O-allyl-2,4-di-O-benzyl-6-O-trityl-α-D-mannopyranoside 
• 111556-46-8 C₈₀H₈₄O₁₃ 

Relevant academic research and scientific papers

Pharmaceutical composition for inhibiting tumor cell growth and application thereof

The invention discloses a pharmaceutical composition for inhibiting tumor cell growth. Its effective components include M6CP-OEt, the structural formula of M6CP-OEt is shown in the description. M6CP-OEt in the pharmaceutical composition can inhibit the gr

Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery

Glycosylated platinum(IV) complexes were synthesized as substrates for GLUTs and OCTs for the first time, and the cytotoxicity and detailed mechanism were determined in vitro and in vivo. Galactoside Pt(IV), glucoside Pt(IV), and mannoside Pt(IV) were highly cytotoxic and showed specific cancer-targeting properties in vitro and in vivo. Glycosylated platinum(IV) complexes 5, 6, 7, and 8 (IC50 0.24-3.97 μM) had better antitumor activity of nearly 166-fold higher than the positive controls cisplatin (1a), oxaliplatin (3a), and satraplatin (5a). The presence of a hexadecanoic chain allowed binding with human serum albumin (HSA) for drug delivery, which not only enhanced the stability of the inert platinum(IV) prodrugs but also decreased their reduction by reductants present in human whole blood. Their preferential accumulation in cancer cells compared to noncancerous cells (293T and 3T3 cells) suggested that they were potentially safe for clinical therapeutic use.

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity

Antibody 2G12 uniquely neutralizes a broad range of HIV-1 isolates by binding the high-mannose glycans on the HIV-1 surface glycoprotein, gp120. Antigens that resemble these natural epitopes of 2G12 would be highly desirable components for an HIV-1 vaccine. However, host-produced (self)-carbohydrate motifs have been unsuccessful so far at eliciting 2G12-like antibodies that cross-react with gp120. Based on the surprising observation that 2G12 binds nonproteinaceous monosaccharide D-fructose with higher affinity than D-mannose, we show here that a designed set of nonself, synthetic monosaccharides are potent antigens. When introduced to the terminus of the D1 arm of protein glycans recognized by 2G12, their antigenicity is significantly enhanced. Logical variation of these unnatural sugars pinpointed key modifications, and the molecular basis of this increased antigenicity was elucidated using high-resolution crystallographic analyses. Virus-like particle protein conjugates containing such nonself glycans are bound more tightly by 2G12. As immunogens they elicit higher titers of antibodies than those immunogenic conjugates containing the self D1 glycan motif. These antibodies generated from nonself immunogens also cross-react with this self motif, which is found in the glycan shield, when it is presented in a range of different conjugates and glycans. However, these antibodies did not bind this glycan motif when present on gp120.

Parasite glycoconjugates. Part 12. Synthesis of deoxy, fluorodeoxy and aminodeoxy disaccharide phosphates, substrate analogues for the elongating α-D-mannopyranosylphosphate transferase in the Leishmania

A set of phosphodisaccharides, structural analogues of the β-D-galactosyl-(1→4)-α-D-mannosyl phosphate 1, are synthesized using the Koenigs-Knorr method for the glycosylation reactions and the glycosyl hydrogenphosphonate method for phosphorylation. The c

THE SYNTHESIS OF THE HEPTOSE REGION OF THE GRAM-NEGATIVE BACTERIAL CORE OLIGOSACCHARIDES

Disaccharides linked α(1-3) and α(1-7) and a trisaccharide linked α(1-7) and α(1-3) have been synthesized from suitably blocked L-glycero-D-mannoheptose derivatives using the trichloroacetimidate approach.

NEW SYNTHESES OF D- AND L-GLYCERO-D-MANNO-HEPTOSES

Three methods for the synthesis of the title compounds starting from benzyl 2,3,4-tri-O-benzyl-α-D-manno-hexodialdo-1,5-pyranoside (7) have been elaborated.Conversion of 7 into the cyanohydrin followed by reduction to give the amine and then deamination gave a derivative of L-glycero-D-manno-heptose in low yield.Condensation of 7 with 2-methylfuran gave two stereoisomeric 6-C-(2-methyl-5-furyl) derivatives.The preponderant stereoisomer was ozonised and then reduced to give a derivative of D-glycero-D-manno-heptose.Condensation of 7 with allyloxymethylmagnesium chloride gave derivatives of both heptoses in good yield and with an L-glycero-D-glycero ratio of 3.2:1.Deprotection of these derivatives gave the heptoses in high yield.

Synthesis of a Model Linear Mannohexaose for the Backbone Structure of Fruit Body Polysaccharide of Tremella fuciformis and Dictyophora indusiata FISCH

Synthesis of linear D-manno-oligosaccharides, O-α-D-Man-3)-O-α-D-Man>n-(1->3)-O-α-D-Man (n=0 4), which correspond to part of the structure of the cell-wall polysaccharide of Tremella fuciformis and Dictyophora indusiata FISCH, is described.

Ditritylation of Methyl and Benzyl α-D-Gluco-, -Manno-, and -Galactopyranosides and Preparation of Their Partially Benzylated Derivatives

The ditritylation of methyl and benzyl α-D-gluco-, -manno-, and -galactopyranosides with trityl chloride in pyridine at 70 deg C proceeds in a regioselective manner to give the 2,6-ditrityl ethers of the glucosides, the 3,6-ones of the mannosides, and bot

Synthesis of O-β-D-Galactopyranosyl-(1->4)-O-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1->3)-D-mannose, a Postulated Trisaccharide of Human Erythrocyte Membrane Sialoglycoprotein

Monoallylation of tributylstannylated benzyl 6-O-trityl-α-D-mannopyranoside (3) was efficiently catalysed by tetrabutylammonium bromide to give the 3-O- (4) and 2-O- (5) allyl ethers in 62 and 15percent yields, respectively.Compound (4) was converted into